Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Repro-Med Systems (REPR)

Add REPR Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/17/2017 4:21:39 PM - Followers: 76 - Board type: Free - Posts Today: 0

Repro-Med Systems, Inc. (dba RMS Medical Products) engages in the design, manufacture, and marketing of proprietary medical devices primarily for emergency medical applications and ambulatory infusion therapy. It offers the FREEDOM60, an infusion system that enables administration of primary immune deficiency by injecting immune globulin under the skin for the home health care industry and patient emergency transportation. The company's FREEDOM60 is also used for treating thalissemia with the drug desferal; for pain control, primarily post-operative epidural pain administration; and for chemotherapy in Europe. Repro-Med also manufactures the FREEDOM60-FM, which contains an electronic flow monitor system that provides occlusion and end of infusion alarm for nursing homes, hospitals, and pediatric ambulatory applications; and the RES-Q-VAC Emergency Airway Suction System, a hand-operated suction device that removes fluids from a patient's airway by attaching the RES-Q-VAC pump to various proprietary sterile and non-sterile single-use catheters sized for adult and pediatric suctioning. In addition, the company offers DENTAL-EVAC for emergency back up suction during a procedure to oral surgeons; and RES-Q-VAC for military situations, such as exposure to chemical weapons of mass destruction. Repro-Med sells its products directly, as well as through a network of domestic and international distributors, and medical device distributors.

Web Site

Main Products

Historical Financials

Quarter    Q1'07(May)    Q2'07(Aug)    Q3'07(Nov)    Q4'07(Feb)     Q1'08(May)    Q2'08(Aug)    Q3'08(Nov)    Q4'08(Feb)    Q1'09(May)   Q2'09(Aug)
Revenue $347,725 $416,009 $457,991 $512,855 $397,417 $605,946 $620,879 $723,436 $699,976 $936,495
Net Income -$207,314 -$89,149 -$67,695 $29,389 -$178,520 $54,367 $61,359 $55,292 $64,784 $275,529

Press Releases
06/11/2007 Higher Medicare Reimbursment for Freedom60 Syringe Infusion Pump -
08/22/2007 Medicare Clarification Reimbursing the Freedom60 with Subcutaneous Immune Globulin - Interview - Required Listening
some tidbits from the interview:

Investment Thesis
1. The company has been hiring like crazy since the middle of last year. This rapid hiring indicates that business is going quite well. Also, I believe that much of this growth has yet to hit the bottom line. As of Feb 2007 they had 17 employees which makes the evidence in the links below look quite bullish.

Picture of hiring sign on building -
Local DD of international expansion and radio advertising -
Currently available positions -
Bookkeeper / Purchasing Associate 4/24/08 -
Customer coordinator posting 10/02/07 -
Assembler hiring posting 08/30/07 -
Assembler hiring posting 7/24/07 -

2. Freedom60 sales have been growing rapidly and I believe will continue to grow rapidly. Here is why:
a. The Freedom60 pump is the most popular pump used for subcutaneous administration of immunoglobulin (SCIG) according to my conversation with CSL Behring who is the maker of the drug used for SCIG. I also verified this with a nurse. The Freedom60 pump is also the least expensive.
b. Vivaglobin® is the first and only immunoglobulin FDA-approved for subcutaneous administration (SCIG). Vivaglobin sales are increasing rapidly according to CSL's financial report.
c. The Freedom60 is the only device approved by Medicare for in-home SCIG treatment. This point was just clarified in August of last year. Also, Medicare reimbursement for the Freedom60 was increased 20 fold in June of 2007.
d. The FREEDOM60 is superior to other pumps for SCIG. Here is what the company says about this in the 10-K: "We have surmised and have recently confirmed anecdotally that the Freedom60 system because of its constant safe pressure design is the ideal technology to infuse this medication regardless of cost. IgG is quite viscous, and the Freedom60 appears to adjust automatically to patient tissue saturation, preventing complications at the administration sites which include pain, swelling, redness and possible tissue damage. Competitive electronic devices, which are also used for this indication, can deliver higher and quite possibly harmful pressures, and will reach occlusion pressures, which will frequently cause the electronic pumps to shut down prior to completing the drug delivery."
e. The most pervasive treatment for Primary Immunity Deficiency right now is IVIG (intravenous). People are switching to SCIG because:
- It is more convenient.
- It costs less.
- There are less adverse reactions.
- Because treatment is generally done weekly instead of monthly the immunity level remains more constant which should help keep the patient more healthy.
f. The company made bullish statements about growing Freedom60 sales in the last 10-Q.
g. According to the immune deficiency organization ( there are more SGIG drugs that are going through trials right now. This should further increase demand for SCIG treatment and Freedom60 sales.

3. They have high gross margins. Last quarter they were 64%. This means that any additional sales rapidly increase earnings.

4. They get a big recurring revenue stream from each Freedom60 that they sell. Annual sales for supplies for the Freedom60 cost on average $252/unit. The list price for the Freedom60 is $399. The revenue information that they put in the 10-K regarding disposable sales indicates that they are thinking big. See the following post for more info:

5. Growing medical businesses are recession proof. I really like businesses like that right now.

More headquarters pics: (11 total)

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
REPR News: Statement of Changes in Beneficial Ownership (4) 11/13/2017 04:07:06 PM
REPR News: Quarterly Report (10-q) 11/03/2017 11:59:52 AM
REPR News: Statement of Changes in Beneficial Ownership (4) 10/03/2017 04:06:56 PM
REPR News: Statement of Changes in Beneficial Ownership (4) 09/15/2017 05:16:56 PM
REPR News: Quarterly Report (10-q) 08/04/2017 04:36:19 PM
#2106   Is there any one still following this stock... erpy 11/17/17 04:21:39 PM
#2105   Another message board said their was a FINRA fwentz 04/28/17 03:57:52 PM
#2104   Any reason for the trading halt this morning? fwentz 04/28/17 03:29:40 PM
#2103   Anyone have an update on REPR? curve 09/01/16 06:27:24 PM
#2101   10k out. I wonder what this was bigpike 05/13/16 01:00:12 PM
#2100   Fear the REPR. willlbone 03/09/16 01:53:50 PM
#2099   Think this was a Bowser Report pick some BooDog 01/04/16 07:46:16 AM
#2098   TOO GOOD TO BE TRUE Roy London 01/03/16 01:53:58 PM
#2097   REPR acting better. Presently at .48. curve 12/30/15 09:35:22 AM
#2096   Medical Stock News REPR 4thQuadrant 09/04/15 12:50:40 PM
#2095   Updates anyone? Any insights on REPR? curve 06/12/15 11:50:38 AM
#2094   Those are very reasonable thoughts in my opinion. quilix 01/20/15 08:28:21 PM
#2093   Though the bottom line growth is missing I blue_skies 01/18/15 06:47:13 PM
#2092   Yes - somebody sold a little yesterday after quilix 01/15/15 11:03:59 AM
#2091   I had been watching this company (was actualyy TheHappyVulcan 01/15/15 11:03:31 AM
#2090   The reason the stock didn't sell off was mrholty 01/15/15 09:04:16 AM
#2089   I don't make it a habit to speculate quilix 01/14/15 09:29:33 PM
#2088   What good is revenue growth if earnings don't SSKILLZ1 01/14/15 07:49:49 PM
#2087   new products coming out this spring. budge 01/14/15 07:21:25 PM
#2086   Even your $0.007 was too optimistic. Way Ex Actuary 01/14/15 07:15:33 PM
#2085   Yup, i hear you. Same shit different Ex Actuary 01/14/15 07:08:59 PM
#2084   Disappointed more did not flow to bottom line. blue_skies 01/14/15 06:02:09 PM
#2083   I'm wondering if word leaked out of strong cliffvb 01/12/15 04:58:09 PM
#2082   Earnings to be released this week. blue_skies 01/12/15 04:17:14 PM
#2081   I tend to agree. On the flip Ex Actuary 12/29/14 04:15:16 PM
#2080   my guess, and this is just speculation, blue_skies 12/29/14 04:09:34 PM
#2079   I'm guessing at least $0.01 based on last Ex Actuary 12/23/14 07:38:45 PM
#2078   My guess is you will see about .007, SSKILLZ1 12/23/14 07:21:12 PM
#2077   Hopefully a little more flows to the bottom Ex Actuary 12/23/14 07:17:45 PM
#2076   we do not know blue_skies 12/23/14 06:53:13 PM
#2075   What's the bottom line for the quarter? Ex Actuary 12/23/14 06:32:40 PM
#2074   great top line growth. blue_skies 12/23/14 05:46:35 PM
#2073   Looks like a new quarterly record on revenue Ex Actuary 12/23/14 12:21:13 PM
#2072   Looks like a new quarterly record on revenue Ex Actuary 12/23/14 12:20:51 PM
#2071   Repro Med Systems, Inc. (Repr) Announces Strong Results SPM555 12/23/14 12:18:02 PM
#2070   wish you had the answer as well my boy larson1 12/08/14 04:55:29 PM
#2069   buddy i have been following the company too... larson1 12/08/14 04:46:41 PM
#2068   I sold out of my position about a quilix 12/05/14 10:20:09 PM
#2065   REPR publication -- Baxter advertising REPR's needle sets Ex Actuary 11/24/14 02:22:41 PM
#2064   My bet is this company is starting to TheHappyVulcan 11/08/14 11:00:26 AM
#2063   From REPR Facebook: Ex Actuary 11/08/14 12:11:40 AM
#2062   ok Thanks.. Nothing else new.. Looks like good erpy 11/07/14 09:39:42 AM
#2061   No rumors that I'm aware of. Ex Actuary 11/07/14 09:29:17 AM
#2060   Hi Raw, over the past few weeks I erpy 11/07/14 09:17:10 AM
#2059   I'd love to see a quarter where we mrholty 10/16/14 04:05:38 PM
#2058   Excellent questions -- wish I had the answers Ex Actuary 10/16/14 02:59:22 PM
#2057   I'd like to think that is a precursor mrholty 10/16/14 02:43:12 PM
#2056   Any thoughts on the jump in inventory? Ex Actuary 10/16/14 12:17:59 PM
#2055   Thanks, holty, I appreciate this summary. It puts TheHappyVulcan 10/16/14 11:51:18 AM
#2054   The real ebola drug companies with suction devices Stockbuilder 10/15/14 05:38:03 PM